Clopidogrel Platelet Function Tests

Methodology Table

December 2011

This table summarizes the platelet function tests by FDA approval, ability to test whole blood without manipulation and difficulty of testing (both of which could limit time of availability) and the turn around times. If FDA approval is important for your institution, you may wish to wait until approval is granted before purchasing an instrument with FDA approval pending.

< Previous Slide

Methodology Table

Next Slide >

 

Jump to section:

• Introduction
• Learning Objectives
• Platelet Function Tests for the Detection of Clopidogrel Resistance¹
• Platelet Function Tests for the Detection of Clopidogrel Resistance
• Caveat: There Is No Perfect Platelet Function Test...
• Problems With Testing For Clopidogrel
• How We Choose a Testing Method
• Methodology Table
• Platelet Function Testing Available at Mayo Clinic Florida
• Light Transmission Platelet Aggregometry Studies (LTA)
• Platelet Aggregation (Cont'd)
• Normal Patient
• Accumetrics VerifyNow Test
• VerifyNow P2Y₁₂ Test
• P2Y₁₂ Test Interferences
• P2Y₁₂ Antagonists²
• Can These Platelet Function Tests Be Used for Ticagrelor (Brilinta/Brilique)?
• PFA-100
• PFA–100 (Cont'd)
• INNOVANCE PFA P2Y
• TEG — Platelet Mapping
• Results of VerifyNow Testing
• 2009–2011 Clopidogrel Response at 30%
• Genetic Testing: Clopidogrel Metabolism
• Clopidogrel Metabolism
• Number of Gene Polymorphisms
• Clopidogrel Metabolism and Genetic Polymorphisms
• Why Do Genetic Testing?
• Clopidogrel Genetics (Cont'd)
• Caveats — Other Reasons for Poor Response to Clopidogrel
• CYP2C19 Polymorphism May Require Another Factor
• Controversy for Clopidogrel
• Warning: Diminished Effectiveness In Poor Metabolizers
• What Does Warning Mean For Clinicians With Patients On Clopidogrel?
• FDA Answer
• More Questions
• Summary
• References
• Questions?
• Disclosure